Login to Your Account

ACR-ARHP Roundup

Tuesday, November 13, 2012
• Infinity Pharmaceuticals Inc., of Cambridge, Mass., released new data from its completed Phase I study of IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription